Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?

Area of Science:

• Urology
• Anesthesiology
• Pain Management

Background:

• Opioid reduction is crucial in radical cystectomy (RC) recovery.
• Liposomal bupivacaine (LB) is a costly, slow-absorbing analgesic with limited comparative studies.
• Standard bupivacaine (SB) formulations offer an alternative for postoperative pain management.

Purpose of the Study:

• To compare postoperative opioid requirements in patients receiving LB versus high-dose SB during RC.
• To evaluate differences in pain scores and length of stay between LB and SB groups.
• To assess the efficacy of SB as a cost-effective alternative to LB for pain control post-RC.

Main Methods:

• A prospective cohort of 28 patients receiving intraoperative high-volume SB was compared to a historical cohort of 34 patients who received LB.
• Primary endpoints included morphine equivalent dose (MED), Numeric Rating Scale (NRS) pain scores, and length of stay.
• All patients were managed under enhanced recovery after surgery (ERAS) protocols.

Main Results:

• No significant differences were observed in MED between SB and LB groups in the postanesthesia care unit (P=0.29) or during the hospital stay (P=0.81).
• Patient-reported NRS pain scores on postoperative days 1, 2, and 3 were similar for both groups (P>0.19).
• Length of stay was comparable between the SB and LB cohorts (P=0.93), with no differences noted in subgroup analyses of open or robotic RC.

Conclusions:

• High-volume SB is as effective as LB in managing postoperative pain and reducing opioid consumption in RC patients under ERAS protocols.
• SB presents a viable, potentially more cost-effective alternative to LB for intraoperative pain management in RC.
• Further research may explore long-term outcomes and cost-effectiveness of SB versus LB in major urologic surgeries.